We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

7 hedge funds and large institutions have $209K invested in Aptevo Therapeutics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more capital inflows, than outflows

Capital inflows: $365K | Capital outflows: $213K

3.32% more ownership

Funds ownership: 0% → 3.32% (+3.3%)

30% less funds holding

Funds holding: 10 → 7 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
7
Holders Change
-3
Holders Change %
-30%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
+$164K
2
HRT Financial
HRT Financial
New York
+$92.1K
3
JP Morgan Chase
JP Morgan Chase
New York
+$37.4K
4
Morgan Stanley
Morgan Stanley
New York
+$31.6K
5
UBS Group
UBS Group
Switzerland
+$5.75K

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$168K
2
Citadel Advisors
Citadel Advisors
Florida
-$20.1K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$7.85K
4
Renaissance Technologies
Renaissance Technologies
New York
-$6.58K
5
Two Sigma Securities
Two Sigma Securities
New York
-$5.04K

APVO Hedge Fund Activity: Q4 2024 in Review

7 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2024, worth a combined $209K — down 9.7% from $231K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of APVO and 4 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Virtu Financial, adding an estimated $164K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $168K sold.

  • 7 institutional investors held Aptevo Therapeutics (APVO) as of Q4 2024, down from 10 in Q3 2024.
  • Funds reported $209K of Aptevo Therapeutics stock for Q4 2024, down 9.7% quarter-over-quarter.
  • 4 funds opened new Aptevo Therapeutics positions in Q4 2024 and 7 closed out, a net change of -3 holders.
  • The largest Aptevo Therapeutics buyer in Q4 2024 was Virtu Financial, an estimated $164K added.
  • The largest Aptevo Therapeutics seller in Q4 2024 was Hudson Bay Capital Management, an estimated $168K sold.

Based on aggregated 13F filings for Q4 2024.